MX2022005594A - Lavados de salinidad elevada durante cromatografia de intercambio cationico para eliminar impurezas relacionadas con el producto. - Google Patents

Lavados de salinidad elevada durante cromatografia de intercambio cationico para eliminar impurezas relacionadas con el producto.

Info

Publication number
MX2022005594A
MX2022005594A MX2022005594A MX2022005594A MX2022005594A MX 2022005594 A MX2022005594 A MX 2022005594A MX 2022005594 A MX2022005594 A MX 2022005594A MX 2022005594 A MX2022005594 A MX 2022005594A MX 2022005594 A MX2022005594 A MX 2022005594A
Authority
MX
Mexico
Prior art keywords
cation exchange
realated
impurities
exchange chromatography
high salt
Prior art date
Application number
MX2022005594A
Other languages
English (en)
Inventor
Natalia Gomez
Malhar R Ambhaikar
Benjamin J Tillotson
Luis Diaz
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2022005594A publication Critical patent/MX2022005594A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • B01D15/426—Specific type of solvent
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2315/00—Details relating to the membrane module operation
    • B01D2315/16—Diafiltration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Water Supply & Treatment (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La invención se refiere a métodos para eliminar impurezas relacionadas con el producto de punto isoeléctrico bajo durante operaciones de purificación de intercambio catiónico.
MX2022005594A 2019-11-07 2020-11-04 Lavados de salinidad elevada durante cromatografia de intercambio cationico para eliminar impurezas relacionadas con el producto. MX2022005594A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962931874P 2019-11-07 2019-11-07
PCT/US2020/058774 WO2021091933A1 (en) 2019-11-07 2020-11-04 High salt washes during cation exchange chromatography to remove product-realated impurities

Publications (1)

Publication Number Publication Date
MX2022005594A true MX2022005594A (es) 2022-06-09

Family

ID=73598212

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005594A MX2022005594A (es) 2019-11-07 2020-11-04 Lavados de salinidad elevada durante cromatografia de intercambio cationico para eliminar impurezas relacionadas con el producto.

Country Status (14)

Country Link
US (1) US20220372071A1 (es)
EP (1) EP4055042A1 (es)
JP (1) JP2022554283A (es)
KR (1) KR20220092958A (es)
CN (1) CN114651007A (es)
AR (1) AR120398A1 (es)
AU (1) AU2020377919A1 (es)
BR (1) BR112022008782A2 (es)
CA (1) CA3160208A1 (es)
CL (1) CL2022001169A1 (es)
IL (1) IL292602A (es)
MX (1) MX2022005594A (es)
TW (1) TW202132323A (es)
WO (1) WO2021091933A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120238730A1 (en) * 2011-03-15 2012-09-20 Abbott Laboratories Integrated approach to the isolation and purification of antibodies
US20170183376A1 (en) * 2014-06-24 2017-06-29 Insight Biopharmaceuticals Ltd. Methods of purifying antibodies
JP6699085B2 (ja) * 2015-03-25 2020-05-27 東ソー株式会社 Ｆｃ結合性タンパク質の精製方法
MX2018015173A (es) * 2016-06-17 2019-07-04 Genentech Inc Purificacion de anticuerpos multiespecificos.
CN110305217B (zh) * 2018-03-27 2022-03-29 广州爱思迈生物医药科技有限公司 双特异性抗体及其应用

Also Published As

Publication number Publication date
CN114651007A (zh) 2022-06-21
IL292602A (en) 2022-07-01
CA3160208A1 (en) 2021-05-14
CL2022001169A1 (es) 2023-01-27
WO2021091933A1 (en) 2021-05-14
KR20220092958A (ko) 2022-07-04
US20220372071A1 (en) 2022-11-24
TW202132323A (zh) 2021-09-01
AU2020377919A1 (en) 2022-06-16
EP4055042A1 (en) 2022-09-14
BR112022008782A2 (pt) 2022-07-26
AR120398A1 (es) 2022-02-09
JP2022554283A (ja) 2022-12-28

Similar Documents

Publication Publication Date Title
SG194460A1 (en) Wash solution and method for affinity chromatography
PH12019502264A1 (en) Fused imidazo-piperidine jak inhibitors compound
MX2021014286A (es) Proteinas multiespecificas.
SG10201900355RA (en) Polypeptide for hydrolytic cleavage of zearalenone and/orzearalenone derivatives, isolated polynucleotide thereof as wellas a polypeptide containing an additive, use of same as well as aprocess
MX2017011121A (es) Uso de lavados alcalinos durante la cromatografia para remover impurezas.
TN2018000035A1 (en) 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridins as bace1 inhibitors
HUE055703T2 (hu) Eljárás hialuronsav tisztítására
MX2018015654A (es) Cromatografía de interacción hidrofóbica para la purificación de oligonucleótidos.
WO2019083318A3 (ko) 개선된 면역글로불린의 정제방법
MX2020006586A (es) Metodos para potenciar la eliminacion de impurezas durante una cromatografia con proteina a.
WO2015195950A8 (en) Lmp7 inhibitors
EA201792640A1 (ru) Устойчивые к действию протеазы липидированные аналоги glp-1
MX2017013143A (es) Uso de acido alcanosulfonico para limpieza en las industrias azucareras.
PH12016500903A1 (en) Novel methods for treating neurodegenerative diseases
EA202191502A1 (ru) Способ получения апиксабана
MX2022005594A (es) Lavados de salinidad elevada durante cromatografia de intercambio cationico para eliminar impurezas relacionadas con el producto.
MX2020005500A (es) Derivados novedosos de piperidinilo como inhibidores de la proteasa 7 ubiquitina especifica.
AR111465A1 (es) Método para la purificación de anticuerpos análogos por el uso de cromatografía de intercambio de cationes
EP4011394A4 (en) METHODS OF TREATMENT OF ALZHEIMER'S DISEASE BY INHIBITING THE UPtake OF AMINO ACIDS BY T-CELLS
MX2022005593A (es) Acondicionamiento de la carga con salinidad elevada durante la cromatografia de intercambio cationico para eliminar impurezas relacionadas del producto.
MX2019005785A (es) Proceso para la purificacion de 1-(4-clorofenil)pirazol-3-ol.
MX2020010343A (es) Proceso para la purificacion de biocomposiciones complejas.
ZA202106824B (en) Method for the purification of acrylamido-2-methyl-2-propanesulphonic acid
MX2022003879A (es) Proceso para elaborar acidos alcansulfonicos.
EP3931203C0 (en) PROCESSES FOR ELIMINATION OF DETERGENTS CONTAINED IN AQUEOUS SOLUTIONS